Is Pfizer Stock in Trouble?
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting headwinds that could send its $145 billion valuation lower in the months and years ahead. And while the markets have done well overall, shares of Pfizer are down some 11% this year.
Is the healthcare stock in big trouble and headed for a greater decline, or are investors perhaps a bit too bearish on the business right now?
Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022), for many investors, it's still seen as a stock whose best days may be behind it. Demand for its COVID vaccine is waning, significantly, and some investors may worry about a potential change in vaccine policy under the incoming Trump administration.
Source Fool.com
